ArsenalBio logo

Arsenal Biosciences, Inc.

Biotechnology

ArsenalBio Stock

Arsenal Biosciences, Inc. is a clinical-stage biotech company specializing in programmable cell therapies for cancer treatment. By leveraging advanced computational and engineering techniques, ArsenalBio aims to develop innovative therapies targeting solid tumors. Their approach integrates diverse scientific expertise to create optimal medicines that improve patient outcomes.

Founded: 2019

ArsenalBio Website

For more ArsenalBio stock information, or to buy or sell private shares, sign up for a MicroVentures account.

ArsenalBio Company Overview

Arsenal Biosciences, Inc. is at the forefront of developing programmable cell therapies to combat cancer. The company's innovative approach centers on utilizing advanced computational and engineering techniques to create therapies specifically targeting solid tumors. By genetically modifying CAR T cells, ArsenalBio enhances the body's natural immune response to precisely attack and eliminate cancer cells. The company's leadership comprises experts from diverse scientific disciplines, combining their extensive knowledge to drive forward their pioneering treatments. This multidisciplinary team, with expertise in biotechnology, clinical development, and manufacturing, ensures that ArsenalBio’s therapies are not only cutting-edge but also scalable and effective. ArsenalBio is dedicated to pushing the boundaries of cancer treatment through a collaborative and integrative approach. Their mission is to create optimal medicines that significantly improve patient outcomes. By leveraging the latest advancements in science and technology, ArsenalBio aims to provide new hope to patients facing the challenges of solid tumors. Central to ArsenalBio's strategy is the belief that combining deep biological insights with advanced engineering can lead to breakthroughs in how cancer is treated. This integrative method allows for the development of highly specific cell therapies that are tailored to the unique characteristics of each patient's cancer. ArsenalBio’s commitment to innovation is evident in their rigorous research and development efforts, which are aimed at creating therapies that are not only effective but also safe and accessible. Their focus on solid tumors, a particularly challenging area in cancer treatment, underscores their dedication to addressing some of the most pressing needs in oncology. Through their groundbreaking work, ArsenalBio is setting new standards in the field of cell therapy, continually striving to transform the landscape of cancer treatment and improve the lives of patients worldwide.

Management Team

Kenneth Drazan Co-Founder, Chief Executive Officer
Tarjei Mikkelsen, Ph.D. Chief Technology Officer
Susie Jun, Ph.D. Chief Medical Officer
Nick Haining Co-Founder, Chief Scientific Officer
Bee Nguyen Chief People Officer
Tim Sirichoke Chief Technology Operations Officer

Funding Information

News

ArsenalBio Named to Endpoints 11 List as One of the Top Biotechs of 2023 • Arsenal Bio

ArsenalBio announced that it has been named to the Endpoints 11, one of the 11 top biotechs of 2023. This is an annual honor selected by the editors of Endpoints News for the most promising and ambitious early-stage companies in the biotech industry.

ArsenalBio Announces Presentations Highlighting Preclinical Data on AB-1015 and AB-2100 at ASGCT Annual Meeting • Arsenal Bio

ArsenalBio announced that it will present preclinical data on its ICT cell therapies, AB-1015 and AB-2100, in an oral abstract session and three posters at the American Society of Gene and Cell Therapy (ASGCT) annual meeting in Los Angeles, Calif., May 16-20, 2023.

ArsenalBio Announces Presentation of Six Abstracts at AACR Annual Meeting Highlighting Programmable Cell Therapy Progress • Arsenal Bio

ArsenalBio announced the presentation of six abstracts at the American Association for Cancer Research (AACR) annual meeting in Orlando, Fla., April 14-19, 2023. These data demonstrate the company’s continued progress towards the enhancement and clinical development of its unique integrated circuit T cell approach for diseases beyond ovarian cancer, including kidney cancer and other solid tumors.

Arsenal Biosciences Announces Joint Discovery Collaboration with Genentech to Identify Features of Successful T-Cell Therapies for Oncology • Arsenal Bio

ArsenalBio announced a multi-year collaboration with Genentech, a member of the Roche Group. The companies will deploy ArsenalBio’s proprietary technology for high-throughput screening and engineering of T cells, to identify critical success circuits in T cell-based therapies.

Arsenal Biosciences Closes $220 Million Series B Financing to Advance Programmable Cell Therapy Programs into Clinical Development • Arsenal Bio

ArsenalBio announced the close of a $220 million Series B financing round.